France opened its medical cannabis experiment in March 2021 and planned to run it for two years. More than five years later, the permanent framework still isn't in force. Patients still enrolled from the pilot are covered by a transitional scheme, and no new patients have been enrolled since the end of 2024.
France's medical cannabis market isn't open to commercial imports yet. When it opens, Canadian flower will reach French patients through a French pharmaceutical establishment, under an ANSM import authorisation and a matching export permit from Health Canada under the Cannabis Act. Two steps still stand in the way: publication of the reimbursement decree and a product-by-product opinion from the Haute Autorité de Santé (HAS).
Where France's medical cannabis framework stands in 2026
The legal base already exists. France's 2024 social security financing law makes cannabis-based medicines subject to an ANSM authorisation lasting five years, renewable for further five-year periods. Access stays narrow by design: last-line treatment only, with the first prescription written in a hospital.
The implementing texts are the problem. In March 2025, France notified the European Commission of a decree setting the authorisation framework and two orders covering pharmaceutical specifications, authorised indications, cultivation and traceability. In January 2026, the government told the National Assembly that the decree on cannabis-based medicines had been validated by the Conseil d'État. The decree on reimbursement was a separate file.
That second decree was finalised in mid-June 2026. According to the industry group UIVEC, it was sent to the Conseil d'État on 30 June for review after the summer break, with publication expected at the start of the school year. By mid-September, the French outlet Newsweed reported it could not confirm the file had been delivered, and the Ministry of Health didn't respond. That left eleven weeks with no public update on a text the government had said would be published at the start of the school year.
| Date | Milestone | What it means for suppliers |
|---|---|---|
| March 2021 | Experiment launches | Selected suppliers provide product free of charge |
| End of 2024 | New patient enrolment stops | Only continuity patients remain |
| March 2025 | Texts notified to the European Commission | Framework drafted, not in force |
| 30 June 2026 | Reimbursement decree sent to the Conseil d'État | Pricing route depends on its publication |
| 31 December 2026 | Planned end of pilot patient coverage | Political pressure to publish rises |
| October-November 2026 | HAS reimbursement opinion, as originally planned | Likely to slip with the decree |
Each step in the table waits on the one before it, so a three-month delay at the Conseil d'État becomes a three-month delay in first commercial orders. Plan France revenue for 2027 at the earliest.
The France supply route for a Canadian LP: 4 steps
France didn't create a separate cannabis licensing regime. It placed cannabis inside its existing pharmaceutical system, which means a Canadian producer can't sell directly to French pharmacies. The route below follows the model the pilot used and the framework notified in 2025.
1. Partner with a French pharmaceutical establishment
In the pilot, each supplier had to sign a partnership with a pharmaceutical establishment located in France. That partner held the status of operator (exploitant), acted as importer where the product came from outside the EU, and held a narcotics authorisation for medical cannabis. It distributed to participating pharmacies and hospital pharmacies. Aurora's French partner, Ethypharm, also handled pharmacovigilance.
2. Secure the two-permit chain
Every shipment needs an ANSM import authorisation for narcotic substances and a Health Canada export permit that matches it. Quantities also have to fit France's annual estimates filed with the INCB. If you haven't run this sequence before, our guide to the two-permit chain covers the order of filings.
3. Meet EU-GMP and EU batch release
Flower entering France enters the EU, so the importer's Qualified Person has to certify each batch against EU-GMP expectations. The pilot required GMP or an equivalent, internationally recognised reference. Our pieces on EU-GMP certification for a Canadian facility and QP batch release set out what that involves on the Canadian side.
4. Support the product authorisation and reimbursement file
The French partner applies to ANSM for the five-year product authorisation, and the HAS assesses each product's benefit for reimbursement. Your role is the data: specifications, stability results, batch history and certificates of analysis that hold up under a pharmaceutical review.
Step 3 is where most Canadian LPs will lose time. Aurora is a Canadian company, yet the flower it supplied to the French pilot came from its EU-GMP site in Odense, Denmark. French partners put a high value on settled GMP status, and that pilot chose an EU site to get it. If you don't already hold EU-GMP certification or a contract with an EU-GMP site, France isn't a 2027 market for you.
What French buyers asked of dried flower in the pilot
The pilot specifications are the best guide to what a French pharmaceutical partner will ask for once the market opens. They were strict on route of administration and on chemical profile.
Dried flower was authorised for inhalation by vaporisation only. Smoking was excluded, and flower suppliers had to state whether they could provide a vaporiser to every patient for the length of the experiment. Pilot patients received a Storz and Bickel device. Expect any commercial dossier to be built around a named vaporiser and a defined method of use.
The pilot also set two flower categories:
- THC above 8% with CBD below 1%
- Balanced flower with both THC and CBD above 5%
Production standards followed the European pharmaceutical model. Suppliers had to meet GACP for cultivation, GMP for manufacturing and the relevant parts of the European Pharmacopoeia. If your specifications aren't yet written against the Ph. Eur. cannabis flower monograph, start there.
Check your portfolio against both categories before you approach a partner. A supplier with only high-THC cultivars covers half of what France defined.
Reimbursement will decide which products sell
At Cannabis Europa in Paris in February 2026, UIVEC outlined the draft reimbursement model. Coverage would be set at 65%, 30%, 10% or 0%, matching a major, moderate, minor or insufficient benefit rating from the HAS. The rating is given per product, not per category.
The HAS review is scoped to five last-resort situations: treatment-resistant epilepsy, cancer-related symptoms, refractory neuropathic pain, painful spasticity linked to central nervous system disorders, and advanced palliative care. French sources put the potential patient population above 400,000 if the framework enters general law. The experiment itself was designed for up to 3,000 patients.
The HAS rating decides how much of that population a product can reach. A product rated insufficient benefit receives 0% coverage, so the patient pays the full price in a market where pilot product was supplied free. Your clinical and quality documentation will shape your price as much as your cultivation does. Germany showed how fast payer rules move flower demand when its statutory insurers stopped reimbursing dried flower on 30 July 2026, as covered in our guide to the German flower reimbursement ban.
AlphaLeaf is a Health Canada Licensed Producer based in Montreal, growing premium indoor, hand-trimmed flower from refined genetics. We hold export authorisation under the Cannabis Act and keep the ISO/IEC 17025 batch testing and full traceability records that an EU importer's Qualified Person reviews before release.
If you're an EU importer or a French pharmaceutical establishment preparing for the French framework, talk to our export team. The decree will come. Supplier shortlists form first.
Frequently Asked Questions
Can Canadian Licensed Producers export medical cannabis to France in 2026?
Not into an open commercial market yet. France's permanent framework still awaits its reimbursement decree, and access is limited to patients carried over from the pilot. When the market opens, a Canadian LP will need a French pharmaceutical establishment as partner, an ANSM import authorisation and a matching Health Canada export permit.
Does France require EU-GMP certification for imported cannabis flower?
The pilot required GMP or an equivalent, internationally recognised reference, and flower entering France must pass EU batch release by the importer's Qualified Person. In practice, French partners have favoured EU-GMP certified supply. The pilot's main flower supplier shipped from an EU-GMP site in Denmark.
Who issues cannabis import authorisations in France?
The ANSM, France's national medicines agency, issues import authorisations for narcotic substances, including medical cannabis. The French pharmaceutical establishment that imports the product must also hold a narcotics authorisation covering medical cannabis.
When will medical cannabis be reimbursed in France?
Reimbursement depends on publication of the coverage decree and a product-by-product opinion from the HAS. The decree was sent to the Conseil d'État at the end of June 2026, and the HAS opinion was originally expected in October or November 2026. The draft model sets coverage at 65%, 30%, 10% or 0%.
Which forms of cannabis flower are allowed under the French framework?
In the pilot, dried flower was authorised for inhalation by vaporisation only, and smoking was excluded. Flower fell into two categories: THC above 8% with CBD below 1%, and balanced flower with both THC and CBD above 5%.
